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Purinergic signaling plays a key role in inflammatory processes and modulates immune
responses against a variety of bacterial and eukaryotic parasites. Here we highlight the role
of purinergic receptor activation in infection and autoimmune diseases. Purinergic
signaling and inflammasomes modulate the host immune response against chlamydial
infections. In addition, increasing evidence suggests that purinergic signaling contributes
to Schistosomiasis morbidity, a neglected tropical disease caused by parasitic worms called
schistosomes. Finally, the P2X7 receptor and NLRP3 inflammasome have been described to
be involved in the pathogenesis of systemic lupus erythematosus, suggesting that these
signaling pathways as suitable therapeutic targets for management and treatment of
different immune diseases.The initial reports on Purinergic Signaling date from the 1920s,
when Drury and Szent-Gyorgyi [1] described the effects of
adenine compounds on the circulatory system of mammals.
In the 1950s, adenosine triphosphate (ATP) was described as a
possible neurotransmitter based on studies that showed its
release from sensory nerves [2,3]. However, the effects of
purines on intercellular signaling responses were only recog-
nized in the 1970s, after the studies published by Burnstock
et al. [4], which culminated in the development of the puri-
nergic hypothesis [5].
Since then, especially in the last three decades, purinergic
signaling has been widely studied in various physiological
and pathological conditions of different tissues [6]. Today,of the Federal Universit
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/by-nc-nd/4.0/).we know that extracellular adenine nucleotides and the
nucleoside adenosine modulate neuronal and non-neuronal
mechanisms, such as immune responses and inflammation,
through purinergic receptors [7].
The first report on the involvement of extracellular ATP in
inflammatory responses also dates from the 1970s, when
Dahlquist and Diamant [8] showed that extracellular ATP
induced histamine release inmast cells. Further, also studying
mast cells, Cockcroft and Gomperts [9] reported the expres-
sion of a specific receptor for extracellular ATP, later identified
as the P2X7 subtype.
Currently, nucleotides are described as extracellular
signaling molecules, which are essential for the initiation andy of Rio de Janeiro, Health Sciences Center, G. Block, Av. Carlos
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in activation and recruitment of leukocytes to the sites of
infection, as well as the production of inflammatory media-
tors, such as IL-1b release following inflammasome activation
[10,11]. Extracellular ATP is now accepted as a proin-
flammatory molecule that acts as a “danger signal” in the
extracellular medium and modulates immune responses
against a variety of bacterial and protozoan parasites
[10,12e14].
In this forum, we have selected three elegant reviews that
highlight the role of purinergic receptor activation in infection
and autoimmune disease. Pettengill and co-authors [15] re-
view how purinergic signaling and inflammasome activation
affects the host immune response against chlamydial infec-
tion. Bacterial species belonging to the family Chlamydiaceae
are obligate intracellular pathogens, which induce prolonged
localized inflammation and tissue damage. Chlamydiae are
sensitive to changes in the normal cellular function of their
hosts. Therefore, the activation of purinergic signaling re-
sponses, as well as the assembly of the inflammasome and
subsequent caspase activation that in turn processes pro-IL-
1b into its mature form, significantly influence the efficiency
of chlamydial infection. In another important review, Silva
[16] highlights the role of purinergic signaling in schistoso-
miasis. This neglected tropical chronic inflammatory disease
is caused by a protozoan parasite belonging to the genus
Schistosoma. As discussed by Silva, increasing evidence sug-
gests that changes in extracellular nucleotide metabolism
and, consequently, in the activation and function of both P1
and P2 purinergic receptors (e.g. the P2X7 receptor) contribute
to disease morbidity. Finally, Di Virgilio and Giuliani [17]
discuss the crucial role of the P2X7 receptor and NLRP3
inflammasome in the development of autoimmunity and tis-
sue damage in systemic lupus erythematosus.
In summary, the aim of this forum is to provide a repre-
sentative overview of the contribution of purinergic signaling
and inflammasome activation to inflammatory and immune
responses during infection by extracellular and intracellular
parasites and autoimmune disease. In addition, such reviews
have clinical relevance to the biomedical area since they point
to purinergic signaling and inflammasomes as suitable ther-
apeutic targets for management and treatment of different
immune diseases.Conflicts of interest
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